Moneycontrol PRO
you are here: HomeAuthor

Viswanath Pilla

Principal Correspondent

Moneycontrol News

Immunocompromised people may need COVID-19 vaccine booster shots: Experts

BUSINESS

Immunocompromised people may need COVID-19 vaccine booster shots: Experts

All people may not need a third dose or booster shot against COVID-19. India’s priority remains getting its adult population fully vaccinated with two doses.

Veeda Clinical Research files DRHP for Rs 831.6 crore IPO

BUSINESS

Veeda Clinical Research files DRHP for Rs 831.6 crore IPO

The company intends to utilise the proceeds to repay debt, fund capital expenditure, invest in/fund further acquisitions by subsidiary Bioneeds and fund working capital requirements

Explainer: What is Ayushman Bharat Digital Mission, what this means to patients and concerns

BUSINESS

Explainer: What is Ayushman Bharat Digital Mission, what this means to patients and concerns

The digital health ID, which creates a health account, will ensure that old medical records are not lost, as every record will be stored digitally. Though the govt says no medical practitioner will be able to access a citizen’s health data without his consent, there are concerns.

Bharat Biotech says working with WHO to obtain clearance, no word on approval delays

BUSINESS

Bharat Biotech says working with WHO to obtain clearance, no word on approval delays

Bharat Biotech has said it doesn't 'find it appropriate to speculate or comment on the regulatory approval process and its timelines' after reports emerged of a possible delay in WHO approval

Biocon gets 6 observations from USFDA for its Malaysian facility in pre-approval inspection

BUSINESS

Biocon gets 6 observations from USFDA for its Malaysian facility in pre-approval inspection

"We are confident of addressing these observations through procedural enhancements and an appropriate Corrective and Preventive Action Plan (CAPA), which will be submitted to the US FDA in the stipulated time," Biocon spokesperson said.

Government’s free vaccination drive kills market for private hospitals, 25% allocation largely unutilised

BUSINESS

Government’s free vaccination drive kills market for private hospitals, 25% allocation largely unutilised

With the wider availability of vaccines, people prefer to get their jabs at government centres rather than pay for shots at private hospitals.

Healthtech platform Medikabazaar raises $75 million from Creagis, CDC Group

BUSINESS

Healthtech platform Medikabazaar raises $75 million from Creagis, CDC Group

The current investment will be utilized to strengthen Medikabazaar’s digital capabilities, deepen the supply ecosystem, technology driven distribution channels and bolster capacity to provide a wider range of leading-edge quality medical supplies across diverse geographical regions.

J&J says launch date of COVID-19 shots in India not decided, still in talks with govt

BUSINESS

J&J says launch date of COVID-19 shots in India not decided, still in talks with govt

COVID-19 vaccines would be on the agenda of the Quad meeting scheduled on September 24 between the heads of the governments of the US, India, Japan and Australia, sources told Moneycontrol

Industry says UK’s non-recognition of Indian vaccine certificates ‘unfair’

BUSINESS

Industry says UK’s non-recognition of Indian vaccine certificates ‘unfair’

India is the leading vaccine manufacturer for the world. Not recognising India's vaccine certificate is not acceptable, Dr Alok Roy, Chair of FICCI Health Services Committee, said. India’s digital certification is far more reliable than other countries’ manual systems, tweeted Kiran Mazumdar-Shaw, Chairperson of Biocon.

MSF asks Regeneron to make COVID antibody cocktail affordable; forego patent claims

BUSINESS

MSF asks Regeneron to make COVID antibody cocktail affordable; forego patent claims

Regenron has priced the antiviral cocktail at $820 (Rs 59,750) in India, $2,000 in Germany and $2,100 in the US. It has also filed patent applications in at least 11 low= and middle-income countries

Aurobindo Pharma's subsidiary seeks marketing approval of its first biosimilar product from EMA

BUSINESS

Aurobindo Pharma's subsidiary seeks marketing approval of its first biosimilar product from EMA

Aurobindo Pharma is developing biosimilars for global markets through its subsidiary CuraTeQ Biologics with focus on oncology and immunology segments.

Lupin's Goa plant: USFDA finds certain investigation, material testing deficiencies

BUSINESS

Lupin's Goa plant: USFDA finds certain investigation, material testing deficiencies

Lupin said the company is confident of addressing the observations satisfactorily

WHO panel to review Covaxin data for emergency-use listing on October 5

BUSINESS

WHO panel to review Covaxin data for emergency-use listing on October 5

Inclusion of indigenously developed Covaxin in the WHO list will boost global acceptance of the Covid-19 vaccine.

UK to allow entry to travellers vaccinated with Covishield from October 4

WORLD

UK to allow entry to travellers vaccinated with Covishield from October 4

Indians will still have to take tests on arrival and quarantine for ten days.

Explainer: Why India is relaxing export restrictions on COVID-19 vaccines

BUSINESS

Explainer: Why India is relaxing export restrictions on COVID-19 vaccines

For one, India has to keep its commitment under a global initiative called COVAX. The other reason, as an expert says, is that if India doesn't ease export restrictions, it will benefit China, which is making deeper inroads into low and middle-income countries with vaccine diplomacy.

UK may review its new COVID travel policy for India: Sources

BUSINESS

UK may review its new COVID travel policy for India: Sources

"Everybody knows that it is identical, it is been proven. We have submitted the data to EMA and the UK MHRA. They are reviewing it, I have had a personal consultation with the regulator there, they are going to get back to us shortly," said Adar Poonawalla, CEO of SII.

India to resume exports of surplus COVID-19 vaccines from October under Vaccine Maitri programme

BUSINESS

India to resume exports of surplus COVID-19 vaccines from October under Vaccine Maitri programme

Union health minister Mansukh Mandaviya said more than 30 crore doses will be produced in October and more than 100 crores in the coming quarter.

Adar Poonawalla-backed Mylab acquires point-of-care testing provider Sanskritech

BUSINESS

Adar Poonawalla-backed Mylab acquires point-of-care testing provider Sanskritech

Sanskritech's Swayam is a portable diagnostic and telemedicine point-of-care system that can be used to create a small lab anywhere. This will allow people to test for a wide range of diseases within a few minutes

Biocon, SII deal to extend to exploring partnership in biologics, mRNA vaccines

BUSINESS

Biocon, SII deal to extend to exploring partnership in biologics, mRNA vaccines

Biocon and SII are exploring development and commercialisation of SII's biologic portfolio, considering manufacture of raw materials for vaccines and biologics, and plan to develop and make drugs and vaccines based on mRNA platform.

Sputnik Light single-dose vaccine launch in India may get delayed

BUSINESS

Sputnik Light single-dose vaccine launch in India may get delayed

An expert panel of the Central Drugs Standard Control Organisation asks company to conduct Phase-3 immune-bridging clinical trials on Indian population. Dr Reddy's spokesperson declines to say when the trial will start.

Delayed launch of Glumetza: Lupin settles case for $248 million

BUSINESS

Delayed launch of Glumetza: Lupin settles case for $248 million

The law suits in US courts alleged that the 2012 settlement of patent litigation regarding Glumetza delayed the availability of generic alternatives, causing consumers to pay higher prices for the drug.

DCGI led panel formed to frame new New Drugs, Cosmetics and Medical Devices Bill starts process

BUSINESS

DCGI led panel formed to frame new New Drugs, Cosmetics and Medical Devices Bill starts process

"The committee has decided to conduct a consultative meeting with the Consumer Associations scheduled to held on September 19 between 2 - 4 pm," the notification released by Somani said.

No new side effects found in COVID-19 antiviral Favipiravir: Glenmark

BUSINESS

No new side effects found in COVID-19 antiviral Favipiravir: Glenmark

Glenmark said the time for fever resolution was four days while time for clinical cure was seven days.

Poonawalla-backed Wellness Forever to file for Rs 1,600-crore IPO

BUSINESS

Poonawalla-backed Wellness Forever to file for Rs 1,600-crore IPO

The retail pharmacy chain will file its draft documents by end-September.

Sections
ISO 27001 - BSI Assurance Mark